Experimental drug found to be safe and effective in treating children with MIS-C
Coronavirus
Mass General Brigham Jul 30 2025 In a small trial, Mass General Brigham researchers found a drug designed to treat Celiac disease supported a more rapid return to normal activities for patients following COVID. Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition that can occur after a COVID-19 infection, presenting as high fevers, gastrointestinal symptoms, and life-threatening cardiac injury. A small, randomized clinical trial led by Mass General Brigham
din zilele anterioare